Immutep IMMP Stock
Immutep Price Chart
Immutep IMMP Financial and Trading Overview
Immutep stock price | 1.5 USD |
Previous Close | 2.14 USD |
Open | 2.09 USD |
Bid | 0 USD x 1200 |
Ask | 0 USD x 800 |
Day's Range | 2.09 - 2.17 USD |
52 Week Range | 1.47 - 3.9 USD |
Volume | 243.91K USD |
Avg. Volume | 1.63M USD |
Market Cap | 190.24M USD |
Beta (5Y Monthly) | 2.041762 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.21 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.31 USD |
IMMP Valuation Measures
Enterprise Value | 120.75M USD |
Trailing P/E | N/A |
Forward P/E | -7.888889 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 42.86065 |
Price/Book (mrq) | 2.448276 |
Enterprise Value/Revenue | 27.204 |
Enterprise Value/EBITDA | -3.226 |
Trading Information
Immutep Stock Price History
Beta (5Y Monthly) | 2.041762 |
52-Week Change | 8.67% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.9 USD |
52 Week Low | 1.47 USD |
50-Day Moving Average | 1.86 USD |
200-Day Moving Average | 1.88 USD |
IMMP Share Statistics
Avg. Volume (3 month) | 1.63M USD |
Avg. Daily Volume (10-Days) | 432.84K USD |
Shares Outstanding | 89.31M |
Float | 84.79M |
Short Ratio | 0.15 |
% Held by Insiders | 0% |
% Held by Institutions | 6.09% |
Shares Short | 653.82K |
Short % of Float | N/A |
Short % of Shares Outstanding | 0.72% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 3:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -862.75% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -23.21% |
Return on Equity (ttm) | -39.40% |
Income Statement
Revenue (ttm) | 4.44M USD |
Revenue Per Share (ttm) | 0.05 USD |
Quarterly Revenue Growth (yoy) | -11.50% |
Gross Profit (ttm) | -26627215 USD |
EBITDA | -37424136 USD |
Net Income Avi to Common (ttm) | -36563864 USD |
Diluted EPS (ttm) | -0.29 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 68.38M USD |
Total Cash Per Share (mrq) | 0.78 USD |
Total Debt (mrq) | 952.66K USD |
Total Debt/Equity (mrq) | 1.24 USD |
Current Ratio (mrq) | 8.974 |
Book Value Per Share (mrq) | 0.87 |
Cash Flow Statement
Operating Cash Flow (ttm) | -30356748 USD |
Levered Free Cash Flow (ttm) | -18779684 USD |
Profile of Immutep
Country | United States |
State | NSW |
City | Sydney |
Address | Australia Square |
ZIP | 2000 |
Phone | 61 2 8315 7003 |
Website | https://www.immutep.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
Q&A For Immutep Stock
What is a current IMMP stock price?
Immutep IMMP stock price today per share is 1.5 USD.
How to purchase Immutep stock?
You can buy IMMP shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immutep?
The stock symbol or ticker of Immutep is IMMP.
Which industry does the Immutep company belong to?
The Immutep industry is Biotechnology.
How many shares does Immutep have in circulation?
The max supply of Immutep shares is 154.39M.
What is Immutep Price to Earnings Ratio (PE Ratio)?
Immutep PE Ratio is now.
What was Immutep earnings per share over the trailing 12 months (TTM)?
Immutep EPS is -0.21 USD over the trailing 12 months.
Which sector does the Immutep company belong to?
The Immutep sector is Healthcare.
Immutep IMMP included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Global Market Composite NQGM | 1647.83 USD — |
-5.17
|
— — | 1610.28 USD — | 1681.06 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}